Last reviewed · How we verify

RT001 — Competitive Intelligence Brief

RT001 (RT001) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT1 and SGLT2 inhibitor. Area: Diabetes.

phase 3 SGLT1 and SGLT2 inhibitor SGLT1 and SGLT2 Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

RT001 (RT001) — Biojiva LLC. RT001 is a small molecule drug that targets the SGLT1 and SGLT2 transporters.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
RT001 TARGET RT001 Biojiva LLC phase 3 SGLT1 and SGLT2 inhibitor SGLT1 and SGLT2
Sotagliflozin High Dose Sotagliflozin High Dose University of California, San Diego phase 3 SGLT2 inhibitor SGLT1 and SGLT2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT1 and SGLT2 inhibitor class)

  1. Biojiva LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RT001 — Competitive Intelligence Brief. https://druglandscape.com/ci/rt001. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: